bearish
Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential
410 Views21 Apr 2023 17:47
SUMMARY
- Dechra Pharmaceuticals (DPH LN) received an offer from the Swedish private equity firm EQT regarding a possible all-cash deal, where Dechra shareholders would receive £40.70 per ordinary share in cash.
- Right after the announcement, Dechra shares surged 33%. The shares are currently trading at £37.66, implying 10% upside potential.
- Without EQT offer, based on current financial performance, Dechra has a bleak outlook. Currently, Dechra has average target price of £39.39, implying a spread of just ~5%.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- EQT/Dechra Pharmaceuticals: Recommended Offer02 Jun 2023
- EQT/Dechra Pharmaceuticals: Generous Possible Offer27 Apr 2023
- Dechra Pharmaceuticals (DPH LN): Recent Sell-Off Is a Buying Opportunity; Fundamentals Remain Intact17 Feb 2022
- Dechra Pharmaceuticals (DPH LN): A High-Quality Idea in Companion Animal Healthcare Space12 Nov 2021
x